The cfNDA test was introduced into clinical practice in 2011,most popular in Bulgaria Prenatest and there was rapid uptake in high-risk populations. It is currently used mainly in women considered to be at risk for aneuploidy or other malformations. Recent data demonstrate, however, that the test’s
Although the test has potential as primary screening for all pregnant women it does have some limitations.
It tests only for trisomies 13, 18, 21, and sex chromosomal aneuploidies, but not for some of the alterations associated with intellectual and other disabilities.
The sequencing of fetal DNA requires that a minimum amount of fetal DNA be present in maternal blood. Low fetal DNA fraction, therefore, can lead to a failed test.That’s why the earliest possible time for the test to be taken is by now 9 w.g.
These tests are considered to be the future for detection of fetal anomalies, thoroughly replacing the exciting ones.The only limitations at the moment come from the high price of the tests.